Abstract
The prevention of
Pneumocystis carinii
pneumonia has had a substantial influence on the course of human immunodeficiency virus (HIV) disease.
1
,
2
Although trimethoprim–sulfamethoxazole is the treatment of choice for prophylaxis against
P. carinii
pneumonia, intolerance often limits its use and makes it necessary to use alternative regimens.
3
Dapsone, alone or in combination with pyrimethamine, is a commonly recommended prophylactic regimen for
P. carinii
pneumonia in patients who cannot tolerate trimethoprim–sulfamethoxazole.
4
Dapsone plus pyrimethamine has been shown to be superior to aerosolized pentamidine for the prevention of toxoplasmosis.
5
However, dapsone has limitations: it is less effective than trimethoprim–sulfamethoxazole for the prevention . . .
